Loading...
Please wait, while we are loading the content...
Similar Documents
Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Andrade, Chittaranjan |
| Copyright Year | 2013 |
| Abstract | A small body of literature suggests that clomipramine may usefully augment selective serotonin reuptake inhibitor (SSRI) treatment in obsessive-compulsive disorder (OCD) patients who do not respond to SSRI monotherapy. The combination, however, is associated with the risk of clinically significant drug interactions. Clomipramine can raise the blood levels and hence the adverse effects of most SSRIs, and many SSRIs can raise the blood levels and hence the adverse effects of clomipramine. The latter situation is more important because certain dose-dependent adverse effects of clomipramine, such as seizures, can be life-threatening. This article presents an evidence-based discussion of the pharmacodynamic and pharmacokinetic adverse effects of the SSRI-clomipramine combination along with suggestions for dosing and monitoring when the combination is used in OCD. |
| Starting Page | 210 |
| Ending Page | 220 |
| Page Count | 11 |
| File Format | PDF HTM / HTML |
| DOI | 10.4088/JCP.13f08883 |
| PubMed reference number | 24434100 |
| Journal | Medline |
| Volume Number | 74 |
| Issue Number | 12 |
| Alternate Webpage(s) | http://www.psychiatrist.com/JCP/article/_layouts/ppp.psych.controls/BinaryViewer.ashx?Article=/jcp/article/pages/2013/v74n12/v74n1201.aspx&Type=Article |
| Alternate Webpage(s) | https://doi.org/10.4088/JCP.13f08883 |
| Journal | The Journal of clinical psychiatry |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
